Results 61 to 70 of about 29,271 (207)

Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia. [PDF]

, 2017
BackgroundThe CXCR4-CXCL12 axis plays an important role in the chronic lymphocytic leukemia (CLL)-microenvironment interaction. Overexpression of CXCR4 has been reported in different hematological malignancies including CLL.
Amaya-Chanaga, Carlos I, Amine, Ale-Ali, Castro, Januario E, Choi, Michael Y, Fantin, Valeria R, Gu, Yin, Hallin, Max, Huser, Nanni, Kashyap, Manoj K, Kipps, Thomas J, Kumar, Deepak, Lindquist, Kevin, Liu, Shu-Hui, Pernasetti, Flavia, Rassenti, Laura Z, Simmons, Brett, Smeal, Tod, Yafawi, Rolla, Zhang, Cathy   +18 more
core   +4 more sources

Nanomedicine Meets Immunotherapy: Advancing Adoptive Cell Therapy with Nanoparticles in the Treatment of Cancer with Sustainability Perspectives

Advanced Science, EarlyView.
This review surveys nanoparticle‐based strategies to enhance adoptive cell therapy, particularly CAR‐T cell approaches, in solid tumor treatment. It describes how nanoparticles can improve tumor immunogenicity and T‐cell infiltration while reducing toxicity, and how they enable in vivo CAR‐T cell generation.
Erica Frostegård, Tatiana Bobrova, Amalie Leinebø, Thibault Leray, Shayamita Ghosh, Lorena García‐Hevia, Chiara Puccinelli, Lorenzo Riccio, Jacopo Sorani, Davide Bonifazi, Julien Caumartin, Emmanuel Donnadieu, Florence Gazeau, Roland Hischier, Else Marit Inderberg, Mónica L. Fanarraga, Maria Loustau, Bernd Nowack, Sébastien Wälchli, Cécilia Ménard‐Moyon   +19 more
wiley   +1 more source

Population Pharmacokinetic and Exposure‐Response Analyses of Ibrutinib Combined With Bendamustine and Rituximab in Patients With Mantle Cell Lymphoma

CPT: Pharmacometrics & Systems Pharmacology
Efficacy and safety of ibrutinib 560 mg once daily or placebo combined with bendamustine and rituximab (BR) were assessed in patients with mantle cell lymphoma in a randomized phase 3 study (SHINE).
Per Olsson Gisleskog, Belén Valenzuela, Nicoline Treijtel, Sanjay Deshpande, Todd Henninger, Juan José Perez‐Ruixo   +5 more
doaj   +1 more source

Is now the time for molecular driven therapy for diffuse large B-cell lymphoma? [PDF]

, 2017
INTRODUCTION: Recent genetic and molecular discoveries regarding alterations in diffuse large B-cell lymphoma (DLBCL) deeply changed the approach to this lymphoproliferative disorder.
Ansuinelli, Michela, DE ANGELIS, Federico, DI ROCCO, Alice, Foa, Roberto, Martelli, Maurizio   +4 more
core   +1 more source

Discovery of a Potent Fluorescence Polarization Probe for Identifying USP1 Allosteric Inhibitors

Advanced Science, EarlyView.
This study presents the first ubiquitin‐specific protease 1 (USP1) allosteric fluoroprobe and fluorescence polarization assay, enabling the differentiation of allosteric and catalytic site inhibitors. Further, a novel class of tetrahydroisoquinoline‐based USP1 inhibitors is designed, with compound 14a (USP1 IC50 = 29.9 nM) showing strong selectivity ...
Jiawei Cheng, Peipei Wang, Pengfei Wang, Jiamin Wang, Baiyang Li, Daqing Fang, Jian He, Xiaobei Hu, Weijuan Kan, Yubo Zhou, Chunpu Li, Jia Li, Hong Liu   +12 more
wiley   +1 more source

Cobimetinib and trametinib inhibit platelet MEK but do not cause platelet dysfunction [PDF]

, 2018
The MEK inhibitors cobimetinib and trametinib are used in combination with BRAF inhibitors to treat metastatic melanoma but increase rates of hemorrhage relative to BRAF inhibitors alone.
Bye, Alex P., Donaghy, Dillon, Gibbins, Jonathan M., Kriek, Neline, Osborne, Ashley A., Sage, Tanya, Unsworth, Amanda J.   +6 more
core   +4 more sources

Real-World Clinical Outcomes and Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Single-Center Retrospective Study

Medicina, 2023
Background and Objectives: The treatment of chronic lymphocytic leukemia (CLL) has acquired new targeted therapies. In clinical trials, ibrutinib improved outcomes safely. Real-world data called for a reappraisal of ibrutinib strategies.
Ana-Maria Moldovianu, Razvan Stoia, Mariana Vasilica, Iulia Ursuleac, Sorina Nicoleta Badelita, Andra Alina Tomescu, Oana Diana Preda, Alexandru Bardas, Mihaela Cirstea, Daniel Coriu   +9 more
doaj   +1 more source

Dissecting Pirtobrutinib Resistance in Mantle Cell Lymphoma Through Single‐Cell Multi‐Omics

American Journal of Hematology, EarlyView.
ABSTRACT Pirtobrutinib (PBN), a non‐covalent BTK inhibitor, has been approved by the FDA for relapsed/refractory mantle cell lymphoma (MCL); however, resistance to PBN has been observed. To dissect the molecular dynamics driving PBN resistance, we performed integrative single‐cell multi‐omic profiling (scRNA‐seq, scATAC‐seq, and scDNA‐seq) on ...
Fangfang Yan, Yang Liu, Heng‐Huan Lee, Wei Wang, Joseph McIntosh, Yijing Li, Jovanny Vargas, Yue Fei, Sairah Ahmed, Lukas M. Simon, Michael Wang   +10 more
wiley   +1 more source

Dialog between mantle cell lymphoma cells and lymphoma-associated macrophages underlies ibrutinib resistance

Journal of Advanced Research
Introduction: Patients with mantle cell lymphoma (MCL) frequently develop resistance to ibrutinib. Lymphoma-associated macrophages (LAMs) may play a causal role in this resistance but remain underexplored in current literature.
Xiaoqing Sun, Caiqin Wang, Jianghua Cao, Jing Li, Gang Ma, Xianqiu Wu, Peng Sun, Yu Wang, Jiajia Huang, Robert Peter Gale, Zhiming Li   +10 more
doaj   +1 more source

Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI

Haematologica, 2018
Ibrutinib and acalabrutinib are irreversible inhibitors of Bruton tyrosine kinase used in the treatment of B-cell malignancies. They bind irreversibly to cysteine 481 of Bruton tyrosine kinase, blocking autophosphorylation on tyrosine 223 and ...
Phillip L.R. Nicolson, Craig E. Hughes, Stephanie Watson, Sophie H. Nock, Alexander T. Hardy, Callum N. Watson, Samantha J. Montague, Hayley Clifford, Aarnoud P. Huissoon, Jean-Daniel Malcor, Mark R. Thomas, Alice Y. Pollitt, Michael G. Tomlinson, Guy Pratt, Steve P. Watson   +14 more
doaj   +1 more source